Kornimate/medical-research-clean huggingface dataset:
my ms toolkit: a symptom self-management program for multiple sclerosis

Conditions: Multiple Sclerosis

Summary: my ms toolkit is a web-based symptom self-management program for persons with multiple sclerosis. this study is evaluating various aspects of my ms toolkit and how it impacts symptom self-management in multiple sclerosis. the research team believe that the toolkit will be feasible, acceptable, and beneficial to participants.

study participants will be asked to use a newly developed web-based symptom self-management program, called the my ms toolkit, for 12 weeks. participants will also be asked to complete online surveys throughout the study. the my ms toolkit includes 8 modules that describe symptom self-management strategies. participants will explore the my ms toolkit on their own, following the prompts and guides built into the program, and are encouraged to practice and apply the skills learned. the study can be done from participants' homes using a reliable internet-connected device. no travel is required.

Eligibility criteria:
inclusion criteria: * multiple sclerosis * have access to a reliable, internet-connected device (e.g. computer, tablet). (note: this study is conducted electronically and is not location dependent.) * one or more of the following: 1. moderate/moderately severe depressive symptoms 2. chronic pain 3. presence of significant fatigue symptoms * read, speak and understand english. exclusion criteria: * significant cognitive impairment * current psychotherapy for symptoms

Keywords: self-management web-based program
patient navigation in the adolescent and young adult (aya) cancer population

Conditions: Cancer

Summary: the purpose of this study is to develop and test a model of patient navigation that investigators hope will address the unique needs of adolescent and young adult (aya) cancer patients and their families by minimizing barriers in their care and potentially improving the outcomes of their treatment while reducing distress and enhancing quality of life. investigators plan to achieve this by increasing access to, and use of, the resources available at moffitt cancer center for aya patients and their families.

up to 80 participants may be recruited to this study at moffitt cancer center to obtain a final sample size of 60 completed participants. participants will be identified in consultation with the patient's primary oncologist and program social worker. a research assistant (ra) will verify eligibility and consent eligible patients. after completing a baseline questionnaire, participants will be randomly placed into one of two groups. both groups will receive their normal care, but one group will also meet with a patient navigator. participants in both groups will be asked to complete a follow-up questionnaire approximately 8 to 10 weeks from when they complete the baseline questionnaire. the follow-up questionnaire will take about 15 to 20 minutes to complete. participation in the study will last about 10 weeks.

Eligibility criteria:
inclusion criteria: * patients 18 to 39 years old. * will undergo chemotherapy and/or radiotherapy and/or surgery with no plans to undergo a transplant procedure within the next 3 months. * have no previous cancer history other than non-melanoma skin cancer. * able to speak and read english. * able to provide written informed consent. exclusion criteria: * does not meet any of the inclusion criteria.

Keywords: cancer among adolescents cancer among young adults adolescents and young adults (aya) quality of life reduce stress patient navigation questionnaire supportive care distress levels support resources satisfaction survey teen cancer
international registry of healthcare workers exposed to covid-19 patients (unity global)

Conditions: SARS-CoV Infection; Covid19

Summary: the international registry of healthcare workers exposed to covid-19 patients (unity global), is an international registry of approximately 10,000 healthcare workers in low- and middle-income countries experiencing increasing numbers of covid-19 cases and commensurate increased exposure to the sars-cov-2 virus among their healthcare worker populations.

the registry will enrol hcws who are experiencing or are expected to experience ongoing and recurrent close contact with confirmed or clinically diagnosed covid-19 patients. recruitment for the registry will aim to enrol a representative distribution of hcws on the front lines of diagnosing and caring for covid-19 patients in both hospitals and community settings, as well as a balanced sample of hcws receiving the most commonly administered putatively prophylactic drug regimens. the registry will collect information on a weekly basis from hcws across a 12-week period following their first known exposure to confirmed or clinically diagnosed covid-19 patients prior to or within 30 days after enrollment. data collection will include the drug regimens being taken by the hcws, information about their level of exposure to covid-19 patients, their personal health status, and other factors such as the use of ppe which would likely impact their risk of developing a sars-cov-2 infection. a standard pharmaco-epidemiological inferential analysis will be conducted treating the registry data as a cohort with dynamic exposure to both prophylactic treatment and to covid-19 infected patients and adjusting for potential confounding. crude and adjusted hazards ratios will be estimated for each of the prophylactic regimens of interest and any observed impact on the risk of infection among hcws based on all statistical inferential models will be reported

Eligibility criteria:
inclusion criteria: healthcare workers will be entered into this study only if they meet all the following criteria: * healthcare workers aged ≥ 18 years. * healthcare workers must be exposed through ongoing and recurrent contact to a confirmed or clinically diagnosed covid-19 patient prior to enrollment, or anticipated within 30 days after enrollment. * healthcare workers must consent to provide data for the registry and must be willing to be contacted/reminded about data entry at each follow-up time point. * healthcare workers must agree to provide a secondary contact for follow-up. exclusion criteria: * a confirmed sars-cov-2 infection or clinically diagnosed covid-19 prior to the first known exposure to confirmed or clinically diagnosed covid-19 patient (index date). * participation in a 'blinded' clinical trial, i.e. unaware of exact treatment received as part of the clinical trial.

Keywords: sars-cov-2 infection sars-cov-2 covid-19 healthcare workers
role of herbal dentifrices in the management of plaque induced gingivitis

Conditions: Gingiva; Infection; Plaque, Dental

Summary: the clinical cross over study involves the use of two herbal based dentifirices moringa and miswak and its efficacy in reducing plaque induced gingivitis. the patients selected are provided with details regarding the research format and consent taken.

the clinical cross over study involves use of miswak and moringa dentifrices. the patients selected are 30 in no and are selected based on having gingival inflammation due to plaque accumulation. all other cases related to gingival inflammation along with patients with underlying systemic disease are excluded from the study. at baseline, plaque and gingival scores are recorded, followed by giving one of the dentifrice to the patient for brushing. the patients are asked to brush twice a day and asked to report after 72 hrs, following which another recording of plaque and gingival scores are recorded. the patients are then asked to use their own tooth paste for a period of 2 weeks as a wash out period and recalled after this 2 week interval. the patients are then given the second dentifrice and asked to brush for 72 hrs and then asked to report again for a plaque and gingival score evaluation.

Eligibility criteria:
inclusion criteria: * subjects having only plaque induced gingival inflammation exclusion criteria: * subjects having gingival inflammation related to underling systemic diseases * subjects taking medications * gingival inflammation related to other causes

Keywords: miswak moringa plaque gingival bleeding
effectiveness of prehabilitation program for high-risk patients underwent abdominal surgery

Conditions: Abdominal Surgical Patient; High-risk Patient

Summary: despite recent advances, morbidity and mortality associated to major abdominal surgery is significant. a poor physical condition and functional status reduces the ability of a person to cope, mentally and physically, with hospitalization and surgery and may compromise functional recovery, potentially leading to postoperative complications and death. prehabilitation aims to enhance functional capacity preoperatively for better toleration of surgery and to facilitate recovery and eventually the prognosis of the surgical patient. whereas the benefits of cardiopulmonary fitness programs are well established, the accessibility, sustainability of effects, and impact on the surgical outcome of these programs are unsolved issues. wellness programs based on integrated care services supported by information and communication technology (ict) can overcome such limitations. the investigators hypothesized that a prehabilitation program, inducing beneficial effects on exercise capacity, may improve the surgical outcome in high-risk patients. moreover, ict support may contribute to increase the adherence and sustainability of this intervention.


Eligibility criteria:
inclusion criteria: patients over 70 years-old and/or american society of anesthesiologists (asa) health status class iii-iv, with a dasi (duke activity score index) \<46 points, referred for scheduled major abdominal surgery exclusion criteria: * unstable severe co-morbid disease * dementia and psychosis, severe mental disorder or substance abuse or dependence * disabling orthopedic and neuromuscular disease.

Keywords: training wellness aerobic capacity information and communication technology, surgical risk abdominal surgery
unloader one study on knee osteoarthritis hässleholm sweden

Conditions: Osteoarthritis, Knee

Summary: the purpose of this study is to assess the effect of the unloader one brace on the clinical symptoms of patients with knee osteoarthritis (oa) by comparing a functioning brace with a dummy.

the purpose of this study is to assess the effect of the unloader one brace on the clinical symptoms of patients with knee oa by comparing a functioning brace with a dummy. the dummy will be manufactured by össur and has the same look as the real brace, but lacks the fundamental tightening effect of the straps of the real brace (an insert of elastic bands assures this), thereby nullifying its unloading capabilities. in a recent trial by dr. ingvarsson, the brace seemed to lessen the pain from knee oa, but no randomised, controlled studies have been conducted. this is mandatory if the effect of the brace and its use as an accepted treatment for knee oa is to be advocated for general use.

Eligibility criteria:
inclusion criteria: patients fulfilling all criteria listed below will be considered to eligible for participation in the study: * patient, men and women, age 30 to 70 with knee oa not scheduled for surgery who understand the given information and are willing to participate in this study. * signed informed patient consent * bmi \< 35 * knee pain for more than 3 month * patients with knee oa ahlbäck grade 1 and 2 and/or kellgren-lawrence 1 and 2 * patient with arthroscopic oa but do not have regular grade 1 oa exclusion criteria: patient presenting with any of the following will not be included in the study: * prior major surgery to the same knee * patients with a history of stroke or neurological or psychiatric decease that potentially could affect the perception of pain * obesity (bmi \> 35) * active or suspected infection * patients taking opioids or steroids * patients suffering from rheumatoid arthritis or have a immunological depression * patients with other severe medical problems that could affect the perioperative course * the patient had an intraarticular steroid injection in the actual knee during the last 3 months * patient participating in a clinical trial
phase iii trial evaluating radium bromatum homeopathic treatment efficacy on radiodermatitis prevention and treatment for breast cancer women

Conditions: Breast Cancer

Summary: breast cancer is the second most frequent cancer worldwide. principal therapy consists in radiotherapy, but this technic has sides effects as radiodermatitis, concerning about 90 percent of women treated. risk of flushing could be reduced by hygienic rules, but no treatment proved its efficacy to prevent radiodermatitis. homeopathy is popular but also contested. no clinical trial proved its efficacy for this indication. the present study aims at evaluating radium bromatum efficacy (homeopathy), compared to placebo, to prevent radiodermatitis apparition for women treated for breast cancer.

breast cancer is the second most frequent cancer worldwide, and the most frequent in france. principal therapy consists in radiotherapy, that is locoregional, using radiations to kill cancerous cells. radiotherapy has sides effects as radiodermatitis, concerning about 90 percent of women treated. radiodermatitis could be described with three factors : redness, heat, and edema. risk of flushing could be reduced by hygienic rules concerning hydratation, clothes, and toilet. nowadays, no treatment proved homeopathic efficacy to prevent radiodermatitis. this treatment is popular but also contested. no clinical trial proved its efficacy for this indication. the present study aims at evaluating radium bromatum efficacy (homeopathy), compared to placebo, to prevent radiodermatitis apparition for women treated for breast cancer.

Eligibility criteria:
inclusion criteria: * major patient; * indication of curative intent radiotherapy for breast cancer treated with conservative treatment. accepted radiotherapy scheme: 50 gy (main) + 16 gy on the tumor bed (additional dose); * patient affiliated or entitled to a social security scheme; * patient who signed an informed consent form. exclusion criteria: * pregnant or lactating woman; * legal incapacity or limited legal capacity. medical or psychological conditions that do not allow the subject to understand the study and sign the consent * patient followed by a liberal homeopath; * patient with bilateral breast cancer; * patient with in situ breast cancer; * patient with known cognitive impairment; * patient with known allergy and / or intolerance and / or malabsorption to fructose, glucose, galactose; * patient with a known deficiency in sucrase / isomaltase / lactase.

Keywords: homeopathy radium bromatum apis mellifica belladonna radiodermatitis radiotherapy prevention treatment breast cancer
phase 1 study of ngm313 in healthy adult participants

Conditions: Obesity

Summary: the purpose of this study is to determine the safety and tolerability of ngm313, both single dose and multiple doses, in normal healthy overweight and obese adult participants.


Eligibility criteria:
inclusion criteria: * bmi range 27-40 kg/m2, inclusive for the sad module, and 27-40 kg/m2, inclusive for the mad module; * normal clinical laboratory evaluations * normal ecg findings exclusion criteria: * significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder * uncontrolled hypertension defined as sitting blood pressure systolic \> 150 mm/hg and/or diastolic \> 90 mm/hg
yoga for aromatase inhibitor-associated joint pain

Conditions: Breast Cancer

Summary: the purpose of this study is to determine whether it might be practical and useful to investigate the effectiveness of yoga classes in relieving joint pain associated with the use of a class of medications known as aromatase inhibitors.

the study uses a single-arm design. all study participants will be assigned to an intervention condition in which they participate in group iyengar yoga classes for 90 minutes twice per week for 12 weeks (total of 24 classes). study outcomes are assessed: 1) following recruitment but prior to the first yoga class; and 2) within two weeks post-intervention (follow-up). additionally, a brief assessment of pain will be conducted four weeks and eight weeks after the start of yoga classes.

Eligibility criteria:
inclusion criteria: * have been diagnosed with stage 0-iii breast cancer * have completed local and/or adjuvant breast cancer therapy (with the exception of hormonal therapy) at least one month previously * are post-menopausal defined as defined as no menses in the past 12 months * are currently prescribed an aromatase inhibitor (ai) medication (anastrozole, letrozole, or exemestane) by a moffitt-affiliated physician * report joint pain that started or worsened after initiation of ai medication * report worst pain score \> 4 in the preceding week on an 11-point (0-10) numeric rating scale exclusion criteria: * have been diagnosed with another form of cancer (except nonmelanoma skin cancer) in the last five years * have uncontrolled cardiac disease, pulmonary disease, or infectious disease * have physical symptoms or conditions that could make yoga unsafe (i.e., neck injuries, dizziness, shortness of breath, chest pain, or severe nausea) * have a body mass index (bmi) \> 40 kg/m\^2 (based on difficulties severly obese individuals may have with engaging in iyengar yoga poses) * have joint pain attributed to inflammatory arthritic conditions (i.e., rheumatoid arthritis, gout, pseudo-gout) per medical record or patient history * had surgery within the past 3 months * had injections of medication within the last 3 months to joint(s) currently painful * are currently using corticosteroids or opioid medications * are currently attending yoga classes * do not speak or read standard english * are scheduled or are planning to discontinue ai medication in the next 16 weeks * do not have sufficient access to the internet to complete study assessments

Keywords: breast carcinoma stage 0-iii breast cancer post-menopausal aromatase inhibitor (ai) joint pain ai-associated joint pain
barrett's esophagus and esophageal adenocarcinoma, searching for reliable diagnostic rna plasma-based biomarkers

Conditions: Esophageal Neoplasms

Summary: this study is designed to perform a explorative search of the transcriptome to detect new circulating diagnostic sensitive and specific biomarkers in patients with barrett's esophagus or esophageal adenocarcinoma.

by developing new tools for risk-assessing of barrett's esophagus (be) and esophageal adenocarcinoma (eac) in a population at risk, the investigators expect that diagnosis can be done in an earlier stage resulting in an improved 5-year survival. a proof-of-concept rna profiling study will be done in 20 be and eac patients where 2 biomaterials (tissue and plasma) and 2 rna biotopes (micro rna and messenger rna) will be compared. previously validated methodology on small rna and messenger rna capture sequencing on both tissue and plasma will be used to obtain high-quality data. differential expression analysis will be done on tissue and plasma sample data. additional in-depth data-mining will be done, amongst other focusing on structural information encoded in the transcriptome and building a multifeature classifier. these findings will be validated in a large validation cohort, followed by development of a clinical-grade quantitative polymerase chain reaction (qpcr) test, ready for testing in an independent cohort.

Eligibility criteria:
inclusion criteria: * barrett's esophagus with length \> 3cm or esophageal adenocarcinoma histologically proven * adequate mental faculty, allowing to understand the proposed treatment protocol and provide informed consent * age over 18 years * no other concurrent malignant disease * no inclusion in other clinical trials interfering with the study protocol * no concurrent chronic systemic immune or hormone therapy, except neoadjuvant chemotherapy * absence of any severe organ insufficiency * no pregnancy or breast feeding * written informed consent exclusion criteria: * pregnancy or breast feeding * active bacterial, viral or fungal infection * parenchymal liver disease (any stage cirrhosis) * high risk of bleeding during biopsy (anticoagulants, esophageal varices) * esophageal squamous cell carcinoma * helicobacter pylori positive at the time of biopsy sampling * radiofrequency ablation of the oesophagus * psychiatric pathology capable of affecting comprehension and judgement faculty

Keywords: esophageal neoplasms liquid biopsy transcriptome
a open-label study to assess the safety of oral long-term use of sa-001 in pancreatic exocrine insufficiency

Conditions: Pancreatic Exocrine Insufficiency, Chronic Pancreatitis, Pancreatectomy

Summary: this study is to evaluate the safety of 3.0 g/day of sa-001 (to be flexibly increased or decreased with the range from 1.5 g/day to 6.0 g/day), which will orally be administered for 52 weeks to patients with pancreatic exocrine insufficiency caused by chronic pancreatitis in the non-compensatory stage or by pancreatectomy.


Eligibility criteria:
inclusion criteria subjects who complete the s245.3.122 clinical study (excluding discontinued subjects). exclusion criteria subjects who are assessed to be inappropriate for continuing long-term use of sa-001, at the discretion of the investigator or the sub-investigator, because they experienced adverse drug reactions in the s245.3.122 clinical study.

Keywords: sa-001 pancreatic exocrine insufficiency chronic pancreatitis pancreatectomy
efficacy of vibrating capsule in patients with chronic constipation

Conditions: Chronic Constipation

Summary: constipated patients in the participating center from february 2017 to june 2018 (anticipated) were prospectively enrolled. number of defecation per week，bristol score，and colon transmission experiment were compared with the constipated patients before treatment.

constipation affects the quality of life of patients, some patients abuse laxatives or repeated medical treatment, increased medical costs. at present, the main treatment of constipation is to adjust life style, medicine, psychotherapy, biofeedback and surgical treatment. however, the above methods are associated with adverse reactions, and the patient's satisfaction is still low. a new approach is needed to solve this clinical problem. investigators have developed a vibration capsule that can be adjusted in different modes. preliminary animal experiments showed that the capsule was safe and increased the number of defecation. this study is a clinical research for patients with constipation, to explore the effect in different vibrating modes in patients with constipation and tract emptying transmission and its effectiveness.

Eligibility criteria:
inclusion criteria: * adult patients aged form 18 to 80 * clinical diagnosis of functional constipation * must be able to swallow vibrating capsule exclusion criteria: * complex history of gastrointestinal diverticula, obstruction, ulcer, bleeding, stenosis or fistula. * recent use of banned drugs. * patients who are preparing for mri.

Keywords: vibrating capsule efficacy and safety chronic constipation different vibrating modes